How Medicines Law & Policy
is Aiding the Covid-19 Response
is Aiding the Covid-19 Response
European Union Review of Pharmaceutical Incentives:
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
Suggestions for Change
A new briefing paper series from Medicines Law & Policy
EU Review of Pharmaceutical
Incentives: Suggestions for Change
Incentives: Suggestions for Change
Medicines Law & Policy creates tools countries and others looking to increase access to medicines can use to overcome patent barriers when needed.
Medicines Law & Policy maintains a database
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
documenting use of TRIPS Flexibilities
to increase access to medicines worldwide.
Medicines Law & Policy releases analysis,
policy recommendations and tools to aid practitioners
working on universal access to medicines.
policy recommendations and tools to aid practitioners
working on universal access to medicines.
Latest insight from Medicines Law & Policy
Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...
Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...
WTO Covid-19 TRIPS Decision: Some observations
This morning, 17 June at 5 AM the 12th World Trade Organization (WTO) Ministerial Conference (MC12) approved a package of decisions and declarations. The...
Proposed TRIPS waiver a hollow diplomatic compromise with little practical impact
In October of 2020, 9 months into the pandemic, fearing conflicts over intellectual property (IP) related to medical measures to fight the pandemic, India...
The US NIH will share technology with WHO to fight the pandemic
The US National Institutes of Health today committed to sharing several technologies with a World Health Organization body tasked with increasing access to Covid-19...
With technology transfer, 120 companies in low- and middle-income countries could manufacture mRNA vaccines
Recent reporting from the British Medical Journal (BMJ) has revealed efforts by BioNTech – the technology firm behind Pfizer’s projected $100 billion in Covid-19...
Wrapping up 2021 – some noteworthy medicines law and policy events
Welcome to the annual end of the year blog, our highly biased overview of noteworthy events in the field of medicines law and policy....
This work is licensed under